FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097841227> ?p ?o ?g. }

• W2097841227 abstract "Constipation within childhood is an extremely common problem. Despite the widespread use of osmotic and stimulant laxatives by health professionals to manage constipation in children, there has been a long standing paucity of high quality evidence to support this practice.We set out to evaluate the efficacy and safety of osmotic and stimulant laxatives used to treat functional childhood constipation.We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and the Cochrane IBD Group Specialized Trials Register from inception to 10 March 2016. There were no language restrictions. We also searched the references of all included studies, personal contacts and drug companies to identify studies.Randomised controlled trials (RCTs) which compared osmotic or stimulant laxatives to placebo or another intervention, with participants aged 0 to 18 years old were considered for inclusion. The primary outcome was frequency of defecation. Secondary endpoints included faecal incontinence, disimpaction, need for additional therapies and adverse events.Relevant papers were identified and two authors independently assessed the eligibility of trials, extracted data and assessed methodological quality using the Cochrane risk of bias tool. The primary outcome was frequency of defecation. Secondary endpoints included faecal incontinence, disimpaction, need for additional therapies and adverse events. For continuous outcomes we calculated the mean difference (MD) and 95% confidence interval (CI) using a fixed-effect model. For dichotomous outcomes we calculated the risk ratio (RR) and 95% CI using a fixed-effect model. The Chi(2) and I(2) statistics were used to assess statistical heterogeneity. A random-effects model was used in situations of unexplained heterogeneity. We assessed the overall quality of the evidence supporting the primary and secondary outcomes using the GRADE criteria.Twenty-five RCTs (2310 participants) were included in the review. Fourteen studies were judged to be at high risk of bias due to lack of blinding, incomplete outcome data and selective reporting. Meta-analysis of two studies (101 patients) comparing polyethylene glycol (PEG) with placebo showed a significantly increased number of stools per week with PEG (MD 2.61 stools per week, 95% CI 1.15 to 4.08). Common adverse events in the placebo-controlled studies included flatulence, abdominal pain, nausea, diarrhoea and headache. Participants receiving high dose PEG (0.7 g/kg) had significantly more stools per week than low dose PEG (0.3 g/kg) participants (1 study, 90 participants, MD 1.30, 95% 0.76 to 1.84). Meta-analysis of 6 studies with 465 participants comparing PEG with lactulose showed a significantly greater number of stools per week with PEG (MD 0.70 , 95% CI 0.10 to 1.31), although follow-up was short. Patients who received PEG were significantly less likely to require additional laxative therapies. Eighteen per cent (27/154) of PEG patients required additional therapies compared to 31% (47/150) of lactulose patients (RR 0.55, 95% CI 0.36 to 0.83). No serious adverse events were reported with either agent. Common adverse events in these studies included diarrhoea, abdominal pain, nausea, vomiting and pruritis ani. Meta-analysis of 3 studies with 211 participants comparing PEG with milk of magnesia showed that the stools per week were significantly greater with PEG (MD 0.69, 95% CI 0.48 to 0.89). However, the magnitude of this difference was quite small and may not be clinically significant. One child was noted to be allergic to PEG, but there were no other serious adverse events reported. One study found a significant difference in stools per week favouring milk of magnesia over lactulose (MD -1.51, 95% CI -2.63 to -0.39, 50 patients), Meta-analysis of 2 studies with 287 patients comparing liquid paraffin (mineral oil) with lactulose revealed a relatively large statistically significant difference in the number of stools per week favouring liquid paraffin (MD 4.94 , 95% CI 4.28 to 5.61). No serious adverse events were reported. Adverse events included abdominal pain, distention and watery stools. No statistically significant differences in the number of stools per week were found between PEG and enemas (1 study, 90 patients, MD 1.00, 95% CI -1.58 to 3.58), dietary fibre mix and lactulose (1 study, 125 patients, P = 0.481), senna and lactulose (1 study, 21 patients, P > 0.05), lactitol and lactulose (1 study, 51 patients, MD -0.80, 95% CI -2.63 to 1.03), hydrolyzed guar gum and lactulose (1 study, 61 patients, MD 1.00, 95% CI -1.80 to 3.80), PEG and flixweed (1 study, 109 patients, MD 0.00, 95% CI -0.33 to 0.33), PEG and dietary fibre (1 study, 83 patients, MD 0.20, 95% CI -0.64 to 1.04), and PEG and liquid paraffin (2 studies, 261 patients, MD 0.35, 95% CI -0.24 to 0.95).The pooled analyses suggest that PEG preparations may be superior to placebo, lactulose and milk of magnesia for childhood constipation. GRADE analyses indicated that the overall quality of the evidence for the primary outcome (number of stools per week) was low or very low due to sparse data, inconsistency (heterogeneity), and high risk of bias in the studies in the pooled analyses. Thus, the results of the pooled analyses should be interpreted with caution because of quality and methodological concerns, as well as clinical heterogeneity, and short follow-up. There is also evidence suggesting the efficacy of liquid paraffin (mineral oil). There is no evidence to demonstrate the superiority of lactulose when compared to the other agents studied, although there is a lack of placebo controlled studies. Further research is needed to investigate the long term use of PEG for childhood constipation, as well as the role of liquid paraffin. The optimal dose of PEG also warrants further investigation." @default.
• W2097841227 created "2016-06-24" @default.
• W2097841227 creator A5018565270 @default.
• W2097841227 creator A5032527327 @default.
• W2097841227 creator A5036883744 @default.
• W2097841227 creator A5055840412 @default.
• W2097841227 creator A5076494290 @default.
• W2097841227 date "2016-08-17" @default.
• W2097841227 modified "2023-10-16" @default.
• W2097841227 title "Osmotic and stimulant laxatives for the management of childhood constipation" @default.
• W2097841227 cites W1073300758 @default.
• W2097841227 cites W117855786 @default.
• W2097841227 cites W1537972189 @default.
• W2097841227 cites W1552208619 @default.
• W2097841227 cites W1573608423 @default.
• W2097841227 cites W1590329563 @default.
• W2097841227 cites W1709246742 @default.
• W2097841227 cites W1959276090 @default.
• W2097841227 cites W1990888048 @default.
• W2097841227 cites W1991223179 @default.
• W2097841227 cites W1999580880 @default.
• W2097841227 cites W2000459204 @default.
• W2097841227 cites W2008174064 @default.
• W2097841227 cites W2009053760 @default.
• W2097841227 cites W2009245997 @default.
• W2097841227 cites W2017662558 @default.
• W2097841227 cites W2023777910 @default.
• W2097841227 cites W2025687815 @default.
• W2097841227 cites W2027564120 @default.
• W2097841227 cites W2028024674 @default.
• W2097841227 cites W2028610080 @default.
• W2097841227 cites W2039082696 @default.
• W2097841227 cites W2040244187 @default.
• W2097841227 cites W2045780051 @default.
• W2097841227 cites W2048035095 @default.
• W2097841227 cites W2061548348 @default.
• W2097841227 cites W2063978386 @default.
• W2097841227 cites W2064861950 @default.
• W2097841227 cites W2069909494 @default.
• W2097841227 cites W2071102937 @default.
• W2097841227 cites W2073032289 @default.
• W2097841227 cites W2089130161 @default.
• W2097841227 cites W2097683169 @default.
• W2097841227 cites W2097841227 @default.
• W2097841227 cites W2105831596 @default.
• W2097841227 cites W2115438850 @default.
• W2097841227 cites W211930448 @default.
• W2097841227 cites W2125435699 @default.
• W2097841227 cites W2125665617 @default.
• W2097841227 cites W2126028343 @default.
• W2097841227 cites W2130288196 @default.
• W2097841227 cites W2136992691 @default.
• W2097841227 cites W2138334282 @default.
• W2097841227 cites W2142707382 @default.
• W2097841227 cites W2148085720 @default.
• W2097841227 cites W2151296144 @default.
• W2097841227 cites W2154049882 @default.
• W2097841227 cites W2158219831 @default.
• W2097841227 cites W2165010366 @default.
• W2097841227 cites W2193476923 @default.
• W2097841227 cites W2261385830 @default.
• W2097841227 cites W2397589131 @default.
• W2097841227 cites W2409332829 @default.
• W2097841227 cites W2410942880 @default.
• W2097841227 cites W2419108533 @default.
• W2097841227 cites W2439524126 @default.
• W2097841227 cites W2616761452 @default.
• W2097841227 cites W2754475501 @default.
• W2097841227 cites W4230257333 @default.
• W2097841227 cites W4246121942 @default.
• W2097841227 cites W4255815531 @default.
• W2097841227 doi "https://doi.org/10.1002/14651858.cd009118.pub3" @default.
• W2097841227 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6513425" @default.
• W2097841227 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27531591" @default.
• W2097841227 hasPublicationYear "2016" @default.
• W2097841227 type Work @default.
• W2097841227 sameAs 2097841227 @default.
• W2097841227 citedByCount "76" @default.
• W2097841227 countsByYear W20978412272013 @default.
• W2097841227 countsByYear W20978412272014 @default.
• W2097841227 countsByYear W20978412272015 @default.
• W2097841227 countsByYear W20978412272016 @default.
• W2097841227 countsByYear W20978412272017 @default.
• W2097841227 countsByYear W20978412272018 @default.
• W2097841227 countsByYear W20978412272019 @default.
• W2097841227 countsByYear W20978412272020 @default.
• W2097841227 countsByYear W20978412272021 @default.
• W2097841227 countsByYear W20978412272022 @default.
• W2097841227 countsByYear W20978412272023 @default.
• W2097841227 crossrefType "journal-article" @default.
• W2097841227 hasAuthorship W2097841227A5018565270 @default.
• W2097841227 hasAuthorship W2097841227A5032527327 @default.
• W2097841227 hasAuthorship W2097841227A5036883744 @default.
• W2097841227 hasAuthorship W2097841227A5055840412 @default.
• W2097841227 hasAuthorship W2097841227A5076494290 @default.
• W2097841227 hasBestOaLocation W20978412272 @default.
• W2097841227 hasConcept C108797546 @default.
• W2097841227 hasConcept C126322002 @default.
• W2097841227 hasConcept C142724271 @default.
• W2097841227 hasConcept C168563851 @default.

• next